timothy sykes logo

Stock News

10x Genomics Sees Bullish Momentum with Raised Price Targets

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 2/14/2026, 11:24 am ET 2/14/2026, 11:24 am ET | 5 min 5 min read
10x Genomics Sees Bullish Momentum with Raised Price Targets Thumbnail

10x Genomics Inc.’s stocks have been trading up by 7.37 percent, boosted by optimistic market sentiment.

Healthcare industry expert:

Analyst sentiment – positive

10x Genomics (TXG) maintains a substantial market presence in the biotechnology sector despite recent financial challenges. Key financial metrics reveal issues with profitability, such as a negative pretax profit margin of -38.1% and a total profit margin of -11.89%. The gross margin of 68.8% demonstrates strong operational efficiency. Although revenue has become less robust, exhibiting an 8.41% three-year growth rate, TXG’s financial health is reinforced by a robust current ratio of 4.5 and a remarkably low debt-to-equity ratio of 0.11, implying sound financial stability and creditworthiness.

Technically, TXG manifested considerable volatility on February 13, 2026, with its stock experiencing broad price swings, closing at $18.12 despite a high of $20.89 earlier in the week. The predominant trend is downward, indicated by lower lows and close values in recent sessions. Analyzing from a trading strategy perspective, the immediate support and resistance levels to monitor are $17.64 and $20.89, respectively. A breach below support suggests short-selling opportunities, while a rebound above resistance could trigger buy signals, thanks to a catalyzed upward momentum.

Recent announcements paint a nuanced outlook for TXG, with 2026 revenue projections ranging between $600M to $625M, surpassing prior market consensus. Analysts have increased price targets, acknowledging the potential growth stemming from AI demand and partnership-driven innovation. Compared to sector peers, TXG demonstrates resilience within Healthcare’s dynamic landscape. Support at $17 delivers a firm baseline, while $22 marks an aspirational target if it capitalizes efficiently on emerging biotech trends like single-cell consumables. Overall, my outlook aligns positively, grounded in potential growth catalysts and supportive price action metrics.

Candlestick Chart

Weekly Update Feb 09 – Feb 13, 2026: On Saturday, February 14, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 7.37%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

10x Genomics recently disclosed a solid Q4 revenue figure of $166M, topping analyst expectations of $160.35M, despite an earnings per share loss that came in wider than forecasted at 13 cents compared to the anticipated 4 cents. The company navigated a challenging 2025, focusing on strengthening strategic partnerships and leveraging AI demand to fuel future growth. In the broader picture, projections indicate a strong revenue leap in 2026, stretching from $600M to $625M, well above consensus estimates, revealing significant optimism in their business trajectory.

More Breaking News

From the provided key financial ratios, the company showcases a robust gross margin of 68.8%. However, the profitability metrics signal areas of concern with negative pretax and total profit margins, which investors might interpret as hurdles in their profitability journey. The balance sheet reflects strong financial health characterized by a current ratio of 4.5, enabling the firm to comfortably meet its short-term obligations. Analysts are noting the company’s recent revenue performance and strategic moves, like advanced product innovations and AI incorporation, as strong tailwinds driving the stock’s favorable outlook. Multiple firms have adjusted their price targets upwards, with notable increases from Stifel to $20 and Canaccord to $22, affirming confidence in the company’s potential market share expansion. This pivotal financial period, marked by partnerships with entities like PharosAI for cancer research funded partly by the UK government, reflects a versatile growth story for the year ahead.

Conclusion

10x Genomics presents a dynamic growth proposition fueled by strategic partnerships and decisive product advancements. The anticipation for accelerated revenue in 2026, alongside elevated analyst price targets, points to broader market confidence. While the earnings miss tempers immediate euphoria, the underlying fundamentals and strategic foresight suggest a positive trajectory. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” This philosophy is crucial for traders looking to capitalize on emerging opportunities as it highlights the importance of strategic patience and precision. Continued execution on this principle is essential for maintaining momentum, channeling toward future gains for both traders and the market at large.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”